Revenue Breakdown
Composition ()
No data
Revenue Streams
Profitability & Margins
Evaluating the bottom line, Nuvation Bio Inc maintains a gross margin of 74.47%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -430.14%, while the net margin is -425.24%. These profitability ratios, combined with a Return on Equity (ROE) of -52.49%, provide a clear picture of how effectively NUVB converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, NUVB competes directly with industry leaders such as CLDX and STOK. With a market capitalization of $2.03B, it holds a significant position in the sector. When comparing efficiency, NUVB's gross margin of 74.47% stands against CLDX's 100.00% and STOK's 100.00%. Such benchmarking helps identify whether Nuvation Bio Inc is trading at a premium or discount relative to its financial performance.
